An observational study in Adult Severe Asthma Patients Treated in France, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-18.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris — 5 open to participants now, 6 under way, none of them phase 3. Asthma · Assistance Publique - Hôpitaux de Paris.
Among the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris, this one has the largest planned enrollment of the 18 observational ones that give a count, is one of 3 that started in 2019, is one of 18 observational ones, and was the 16th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →5 of the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 4–12
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6+
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 90 across the 13 interventional studies, 113 across the 18 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Asthma by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04763447Assistance Publique - Hôpitaux de ParisShort Treatment with Omalizumab for Severe Asthma | 2027-05-20 |
| NCT06902766Assistance Publique - Hôpitaux de ParisTowards Digital Management of Paediatric Asthma | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Asthma by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The French Society for Respiratory diseases (SPLF), through its Asthma and Allergy working group (G2A), wishes to set up a national cohort of severe asthma patients to describe this population and the use of step 4 and 5 treatment. This study also meets the demand for post - registration studies required by the Health Authorities for biotherapies and bronchial thermoplasty.
Other European or international cohorts of asthmatic patients exist and RAMSES could contribute to data sharing initiatives.
Severe asthma is defined by poorly controlled disease despite treatment with high doses of inhaled corticosteroids, in combination with at least a long acting beta agonist, after optimal management for at least 6 months by an asthma specialist. The diagnosis of severe asthma can only be made after a rigorous evaluation of 6 to 12 months, including the review of diagnosis and treatment, by a pulmonologist, to distinguish difficult asthma from severe asthma.
Severe asthma accounts for 3.5% to 5% of all asthma patients, a population estimated at 150 000 patients in France. This disease is responsible for significant health costs related to asthma treatments, comorbidities, hospitalizations and sick days. The management of severe asthma is complex, multidisciplinary and includes drug treatment, but also the management of side effects of treatment, including oral corticosteroid therapy, and comorbidities of asthma.
Until 2018, omalizumab,systemic continuous oral corticosteroid therapy or inclusion in a therapeutic trial were the ony possibilities offered to severe asthmatic patients beyond the usually recommended and optimized management. In 2018, mepolizumab and reslizumab have been marketed in France, then benralizumab in 2019. They will probably be followed by dupilumab and bronchial thermoplasty. New initiatives to change the history of the disease are also proposed such as specific immunotherapy or long-term use of macrolides. Respiratory rehabilitation is also part of the treatments to be evaluated in some groups of patients.
The description of the use of these treatments, as well as the evaluation of their effectiveness and tolerance in real life conditions is essential. Indeed, their use outside clinical trials raises a number of issues such as the optimal duration of treatment, the maintenance of efficacy over extended periods, the risk and the time to relapse when the treatment is stopped, the possibility to switch from one biotherapy to another in case of insufficient clinical response or to associate them which may prove to be an effective strategy in patients eligible for two biotherapies (allergic and eosinophilic patients).
The cost of these treatments is high. The pharmaco-economic evaluation of severe asthma and its management is another important element. For example, no economic evaluation of the use of omalizumab is currently available in France.
Lastly, the organization of a care network dedicated to severe asthma is being launched in France (severe asthma centers ), on the model of European countries, in order to improve the diagnosis and management of these patients and to reduce the burden of comorbidities of asthma and steroids side effects.It is therefore essential to set up a clinical research structure that will make it possible to obtain clinical data on this population of severe asthma patients and to evaluate all medical practices in real life conditions.
Adult severe asthma patients treated in France
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Or receiving level 5 support (initiating treatment or already treated) :
And / or other complex costs corresponding to the level 5 treatments
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of patients receiving asthma treatment
Severe asthma medication (high dose inhaled corticosteroids / B2LDA, Anti IgE antibody, Anti IL5 antibody, daily oral steroids...); Other asthma medications (long acting anticholinergics, montelukast, theophylline, inhaled corticoids); bronchial thermoplasty.
Time frame: Previous treatment, collected at baseline
Dose of severe asthma treatments
Severe asthma medication (high dose inhaled corticosteroids / B2LDA, Anti IgE antibody, Anti IL5 antibody, daily oral steroids...)
Time frame: At baseline
Duration of asthma treatments
Severe asthma medication (high dose inhaled corticosteroids / B2LDA, Anti IgE antibody, Anti IL5 antibody, daily oral steroids...); Other asthma medications (long acting anticholinergics, montelukast, theophylline, inhaled corticoids); bronchial thermoplasty.
Time frame: Previous treatment, collected at baseline
Other medications
Number of patients receiving antidiabetics, Number of patients receiving antidepressants, Number of patients receiving anti-osteoporotic drugs, Number of patients receiving cardiovascular drugs.
Time frame: At baseline
Asthma-related comorbidities
Prevalence of asthma related comorbidities such as chronic rhinosinusitis, nasal polyps, gastroesophageal reflux, obesity, obstructive sleep apnea respiratory infections, ...
Time frame: At baseline
Non-respiratory comorbidities
Prevalence of non-respiratory comorbidities such as osteoporosis, diabetes , cardiovascular diseases...
Time frame: At baseline
Asthma control test (ACT)
Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 items, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled). Asthma is controlled when the total score is \>20.
Time frame: 12 previous months, collected at baseline
Asthma exacerbations
Number of systemic corticosteroids (SC) courses
Time frame: 12 previous months, collected at baseline
Forced Expiratory Volume in 1 second (FEV1)
Mean FEV1, expressed in ml.
Time frame: 12 previous months, collected at baseline
Number of patients with at least 1 sick leaves due to asthma
Patient-reported sick leaves.
Time frame: 12 previous months, collected at baseline
Number of sick leaves due to asthma
Patient-reported sick leaves.
Time frame: 12 previous months, collected at baseline
Number of patients with long term disease status for asthma
Time frame: At baseline
Intensive care unit hospitalization due to asthma exacerbation
At least one intensive care unit hospitalization for asthma
Time frame: During life, collected at baseline
Number of unscheduled healthcare visits or hospitalization
Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits
Time frame: At 6 months
Number of patients with unscheduled healthcare visits or hospitalization
Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits
Time frame: At 6 months
Number of unscheduled healthcare visits or hospitalization
Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits
Time frame: At 12 months
Number of patients with unscheduled healthcare visits or hospitalization
Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits
Time frame: At 12 months
Number of unscheduled healthcare visits or hospitalization
Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits
Time frame: At 24 months
Number of patients with unscheduled healthcare visits or hospitalization
Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits
Time frame: At 24 months
Number of unscheduled healthcare visits or hospitalization
Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits
Time frame: At 36 months
Number of patients with unscheduled healthcare visits or hospitalization
Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits
Time frame: At 36 months
Number of unscheduled healthcare visits or hospitalization
Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits
Time frame: At 60 months
Number of patients with unscheduled healthcare visits or hospitalization
Inpatient hospitalizations due to asthma including intensive care unit, inpatient hospitalization for other reasons, emergency department visits and unscheduled ambulatory visits
Time frame: At 60 months
Daily dose of corticosteroids
Inhaled corticosteroids, oral corticosteroids (SC) in long term users
Time frame: At 6 months
Daily dose of corticosteroids
Inhaled corticosteroids, oral corticosteroids (SC) in long term users
Time frame: At 12 months
Daily dose of corticosteroids
Inhaled corticosteroids, oral corticosteroids (SC) in long term users
Time frame: At 24 months
Daily dose of corticosteroids
Inhaled corticosteroids, oral corticosteroids (SC) in long term users
Time frame: At 36 months
Daily dose of corticosteroids
Inhaled corticosteroids, oral corticosteroids (SC) in long term users
Time frame: At 60 months
Number of patients with at least 1 other asthma medication
Long acting beta 2 agonists, long acting anticholinergics, montelukast, macrolides, Anti IgE monoclonal antibodies, theophylline.
Time frame: At 6 months
Number of patients with at least 1 other asthma medication
Long acting beta 2 agonists, long acting anticholinergics, montelukast, macrolides, Anti IgE monoclonal antibodies, theophylline.
Time frame: At 12 months
Number of patients with at least 1 other asthma medication
Long acting beta 2 agonists, long acting anticholinergics, montelukast, macrolides, Anti IgE monoclonal antibodies, theophylline.
Time frame: At 24 months
Number of patients with at least 1 other asthma medication
Long acting beta 2 agonists, long acting anticholinergics, montelukast, macrolides, Anti IgE monoclonal antibodies, theophylline.
Time frame: At 36 months
Number of patients with at least 1 other asthma medication
Long acting beta 2 agonists, long acting anticholinergics, montelukast, macrolides, Anti IgE monoclonal antibodies, theophylline.
Time frame: At 60 months
Asthma exacerbations
Systemic corticosteroids (SC) use or doubling the usual dose or at least 48 hours in SC long term users
Time frame: 6 months
Asthma exacerbations
Systemic corticosteroids (SC) use or doubling the usual dose or at least 48 hours in SC long term users
Time frame: At 12 months
Asthma exacerbations
Systemic corticosteroids (SC) use or doubling the usual dose or at least 48 hours in SC long term users
Time frame: At 24 months
Asthma exacerbations
Systemic corticosteroids (SC) use or doubling the usual dose or at least 48 hours in SC long term users
Time frame: At 36 months
Asthma exacerbations
Systemic corticosteroids (SC) use or doubling the usual dose or at least 48 hours in SC long term users
Time frame: At 60 months
Number of patients reporting suboptimal treatment adherence
Patient-reported adherence to asthma treatment. Suboptimal treatment is defined as less treatment received than expected.
Time frame: Through study completion, an average of 5 years
Drug survival rate
Proportion of patients still exposed to treatment
Time frame: At 6 month
Drug survival rate
Proportion of patients still exposed to treatment;
Time frame: At 12 months
Time to drug discontinuation
Median time between the start of treatment and its definitive cessation
Time frame: Reported at 6 month
Time to drug discontinuation
Median time between the start of treatment and its definitive cessation.
Time frame: Reported at 12 month
Asthma control test (ACT)
Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).
Time frame: At 6 months
Asthma control test (ACT)
Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).
Time frame: At 12 months
Asthma control test (ACT)
Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).
Time frame: At 24 months
Asthma control test (ACT)
Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).
Time frame: At 36 months
Asthma control test (ACT)
Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).
Time frame: At 60 months
Number of patients with at least 1 sick leaves due to asthma
Patient-reported sick leaves.
Time frame: At 6 months
Number of sick leaves due to asthma
Patient-reported sick leaves.
Time frame: At 6 months
Number of patients with at least 1 sick leaves due to asthma
Patient-reported sick leaves.
Time frame: At 12 months
Number of sick leaves due to asthma
Patient-reported sick leaves.
Time frame: At 12 months
Number of patients with at least 1 sick leaves due to asthma
Patient-reported sick leaves.
Time frame: At 24 months
Number of sick leaves due to asthma
Patient-reported sick leaves.
Time frame: At 24 months
Number of patients with at least 1 sick leaves due to asthma
Patient-reported sick leaves.
Time frame: At 36 months
Number of sick leaves due to asthma
Patient-reported sick leaves.
Time frame: At 36 months
Number of patients with at least 1 sick leaves due to asthma
Patient-reported sick leaves.
Time frame: At 60 months
Number of sick leaves due to asthma
Patient-reported sick leaves.
Time frame: At 60 months
St. George's Respiratory Questionnaire (SGRQ)
The St. George's Respiratory Questionnaire (SGRQ) is a self-reporting questionnaire validated for evaluating quality of life in asthma. The total score is expressed as a percentage, from 0%, no impairment of life quality, to 100%, maximal impairment.
Time frame: At 6 months
St. George's Respiratory Questionnaire (SGRQ)
The St. George's Respiratory Questionnaire (SGRQ) is a self-reporting questionnaire validated for evaluating quality of life in asthma. The total score is expressed as a percentage, from 0%, no impairment of life quality, to 100%, maximal impairment.
Time frame: At 12 months
St. George's Respiratory Questionnaire (SGRQ)
The St. George's Respiratory Questionnaire (SGRQ) is a self-reporting questionnaire validated for evaluating quality of life in asthma. The total score is expressed as a percentage, from 0%, no impairment of life quality, to 100%, maximal impairment.
Time frame: At 24 months
St. George's Respiratory Questionnaire (SGRQ)
The St. George's Respiratory Questionnaire (SGRQ) is a self-reporting questionnaire validated for evaluating quality of life in asthma. The total score is expressed as a percentage, from 0%, no impairment of life quality, to 100%, maximal impairment.
Time frame: At 36 months
St. George's Respiratory Questionnaire (SGRQ)
The St. George's Respiratory Questionnaire (SGRQ) is a self-reporting questionnaire validated for evaluating quality of life in asthma. The total score is expressed as a percentage, from 0%, no impairment of life quality, to 100%, maximal impairment.
Time frame: At 60 months
Asthma Quality of Life Questionnaire (AQLQ) overall score by Visit
The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions.
Time frame: At 6 months
Asthma Quality of Life Questionnaire (AQLQ) overall score by Visit
The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions.
Time frame: At 12 months
Asthma Quality of Life Questionnaire (AQLQ) overall score by Visit
The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions.
Time frame: At 24 months
Asthma Quality of Life Questionnaire (AQLQ) overall score by Visit
The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions.
Time frame: At 36 months
Asthma Quality of Life Questionnaire (AQLQ) overall score by Visit
The AQLQ is a 32-item disease-specific questionnaire that has been designed to measure the functional impairments that are most troublesome to adults with asthma. Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale. The overall AQLQ score is the mean response to all 32 questions.
Time frame: At 60 months
EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) index score and health state assessment
EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". Pain/discomfort dimension asks how much pain or discomfort the person has, and anxiety/depression dimension asks how anxious or depressed the person is. The respondents self-rate their level of severity for each dimension using three-level (EQ-5D-3L) scale. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).
Time frame: At 6 months
EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) index score and health state assessment
EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". Pain/discomfort dimension asks how much pain or discomfort the person has, and anxiety/depression dimension asks how anxious or depressed the person is. The respondents self-rate their level of severity for each dimension using three-level (EQ-5D-3L) scale. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).
Time frame: At 12 months
EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) index score and health state assessment
EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". Pain/discomfort dimension asks how much pain or discomfort the person has, and anxiety/depression dimension asks how anxious or depressed the person is. The respondents self-rate their level of severity for each dimension using three-level (EQ-5D-3L) scale. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).
Time frame: At 24 months
EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) index score and health state assessment
EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". Pain/discomfort dimension asks how much pain or discomfort the person has, and anxiety/depression dimension asks how anxious or depressed the person is. The respondents self-rate their level of severity for each dimension using three-level (EQ-5D-3L) scale. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).
Time frame: At 36 months
EuroQual 5-Dimension Health Status Questionnaire (EQ-5D) index score and health state assessment
EQ-5D is a standardized instrument for measuring generic health status. The EQ-5D questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". Pain/discomfort dimension asks how much pain or discomfort the person has, and anxiety/depression dimension asks how anxious or depressed the person is. The respondents self-rate their level of severity for each dimension using three-level (EQ-5D-3L) scale. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS).
Time frame: At 60 months
Hospital Anxiety and Depression scale
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Time frame: At 6 months
Hospital Anxiety and Depression scale
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Time frame: At 12 months
Hospital Anxiety and Depression scale
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Time frame: At 24 months
Hospital Anxiety and Depression scale
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Time frame: At 36 months
Hospital Anxiety and Depression scale
The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.
Time frame: At 60 months
Long term adverse Events associated with corticosteroid therapy.
Frequency of relevant medical events such as osteoporosis, diabetes, cardiovascular disease.
Time frame: 60 months
Asthma-related comorbidities
Prevalence of comorbidities such as rhinosinusitis, obesity, gastroesophageal reflux, sleep obstructive apnea syndrome, ...
Time frame: At 6 months
Asthma-related comorbidities
Prevalence of comorbidities such as rhinosinusitis, obesity, gastroesophageal reflux, sleep obstructive apnea syndrome, ...
Time frame: At 12 months
Asthma-related comorbidities
Prevalence of comorbidities such as rhinosinusitis, obesity, gastroesophageal reflux, sleep obstructive apnea syndrome, ...
Time frame: At 24 months
Asthma-related comorbidities
Prevalence of comorbidities such as rhinosinusitis, obesity, gastroesophageal reflux, sleep obstructive apnea syndrome, ...
Time frame: At 36 months
Asthma-related comorbidities
Prevalence of comorbidities such as rhinosinusitis, obesity, gastroesophageal reflux, sleep obstructive apnea syndrome, ...
Time frame: At 60 months
Death and cause of death
Time frame: At 6 months
Death and cause of death
Time frame: At 12 months
Death and cause of death
Time frame: At 24 months
Death and cause of death
Time frame: At 36 months
Death and cause of death
Time frame: At 60 months
Post-procedural adverse Events associated with bronchial thermoplasty
Frequency of post-procedure medical events such as hemoptysis, respiratory symptoms, asthma, prolonged hospitalization
Time frame: Up to 24 hours following the procedure
Post-procedural adverse Events associated with bronchial thermoplasty
Frequency of post-procedure medical events such as hemoptysis, respiratory symptoms, asthma, prolonged hospitalization.
Time frame: From 24 hours to 1 month following the procedure
Long term adverse events associated with bronchial thermoplasty
Frequency of long term medical events such as bronchial stenosis.
Time frame: 60 months
Events of special interest
Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis.
Time frame: From treatment initiation to 3 months following treatment initiation
Events of special interest
Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis.
Time frame: From 3 months to 12 months following treatment initiation
Events of special interest
Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis.
Time frame: From 3 to 5 years following treatment initiation
Blood eosinophil count
Time frame: At baseline
Total immunoglobulin E (IgE)
Time frame: At baseline
Chest computed tomography scan
Dates and description of major findings.
Time frame: At baseline
Forced Vital Capacity (FVC)
Time frame: At baseline
Forced Vital Capacity (FVC)
Time frame: At 6 months
Forced Vital Capacity (FVC)
Time frame: At 12 months
Forced Vital Capacity (FVC)
Time frame: At 24 months
Forced Vital Capacity (FVC)
Time frame: At 36 months
Forced Vital Capacity (FVC)
Time frame: At 60 months
Forced Expiratory Volume in 1 second (FEV1)
Time frame: At 6 months
Forced Expiratory Volume in 1 second (FEV1)
Time frame: At 12 months
Forced Expiratory Volume in 1 second (FEV1)
Time frame: At 24 months
Forced Expiratory Volume in 1 second (FEV1)
Time frame: At 36 months
Forced Expiratory Volume in 1 second (FEV1)
Time frame: At 60 months
FEV1/FVC ratio
Time frame: At baseline
FEV1/FVC ratio
Time frame: At 6 months
FEV1/FVC ratio
Time frame: At 12 months
FEV1/FVC ratio
Time frame: At 24 months
FEV1/FVC ratio
Time frame: At 36 months
FEV1/FVC ratio
Time frame: At 60 months
RV/TLC ratio
Time frame: At baseline
RV/TLC ratio
Time frame: At 6 months
RV/TLC ratio
Time frame: At 12 months
RV/TLC ratio
Time frame: At 24 months
RV/TLC ratio
Time frame: At 36 months
RV/TLC ratio
Time frame: At 60 months
Fractional exhaled nitric oxide (FENO)
Time frame: At baseline
Costs of severe asthma management
Total amount of money, expressed in euros, reimbursed by Social Security ( for treatments, medical visits, radiological or laboratory examinations).
Time frame: Through study completion, an average of 5 years
Started Sep 2019 (actual). Primary completion is estimated for Sep 2024, 60 months after the start.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 60 months is above that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →